Volume : 12, Issue : 08, August- 2025
Title:
PREPARATION AND EVALUATION OF TAPENTADOL HYDROCHLORIDE TRANSDERMAL PATCHES
Authors :
Prema*, Debora, Shahnawaz, Surjith, Arun
Abstract :
The objective of present study was to develop matrix type transdermal therapeutic systems of Tapentadol Hydrochloride using various such as HPMC and Sodium alginate polymers as matrix formers. Results revealed that prepared patches showed good physical characteristics and no drug-polymer interaction was observed. The in vitro release study revealed that F4 formulation showed maximum release in 8 hrs. Formulation F8was subjected for accelerated stability studies. The F4 formulation was found to be stable as there was no drastic change in the Physico-chemical properties of the patches, which was also confirmed by FTIR. Thus, conclusion can be made that stable transdermal patch of Tapentadol Hydrochloride has been developed. F4 formulation showed highest cumulative percentage drug release of 96.89 % were obtained during in vitro drug release studies after 8hrs. The predominant release mechanism of drug through the fabricated matrices was believed to be by diffusion mechanism. Based upon the in vitro dissolution data the F4 formulation was concluded as optimized formulation.
Key words: Tapentadol Hydrochloride, HPMC, Sodium alginate, solvent casting technique, in vitro drug release studies.
Cite This Article:
Please cite this article in press Prema et al., Preparation And Evaluation Of Tapentadol Hydrochloride Transdermal Patches., Indo Am. J. P. Sci, 2025; 12(08).
Number of Downloads : 10
References:
1. Tlxx-Liwes, F. and W. Beyne, Dosage form index; an objective crilerion for evaliiiition of controlled release drug delivery systems, J.Pharm.Sci. 66, 13S.S(I977).
2. Brandau R., Lippoid, B. (Eds.) “Dermal and Transdermal Absorption”, 1st International Symposium”, Munich, 1981. pp. 171-173.
3. Jain NK. Controlled and Novel Drug Delivery. 1st ed. New Delhi: CBS Publisher and Distributors; 2001. p. 100-29.
4. Darwhekar G, Jain DK, Paditar VK. Formulation and evaluation of transdermal drug delivery system of clopidogrel bisulfate. Asian J Pharm Life Sci 2011;1:269-78.
5. Shingade GM, Aamer Q, Sabale PM, Grampurohit ND, Gadhave MV. Review on: Recent trend on transdermal drug delivery system. J Drug Deliv Ther 2012;2:66-75.
6. Sachan R, Bajpai M. Transdermal drug delivery system: A review. Int J Res Dev Pharm Life Sci 2013;3:748-65.
7. Gary W. Transdermal and transdermal-like delivery system opportunities: Today and the future. Drug Delv Technol 2004;3:1-6.
8. Mahato, R.A., Pharmaceutical dosage forms & drug delivery, published by CRS press, Boca Raton, 2002: 196-197.
9. Guy RH, Hadgraft J, Bucks DA. Transdermal drug delivery and cutaneous metabolism, Xenobiotica 1987, 7, 325-343.
10. Chein YW. Transdermal Controlled Systemic Medication. New York and Basel, Marcel Dekker Inc. 1987; 159 – 176.
11. Barry BW “Dermatological Formulations: Percutaneous Absorption”, Drugs and pharmaceutical sciences, Volume – 18, Marcel Dekker, Inc. 1983:1-39.
12. Aulton ME, Pharmaceutics: The Science of Dosage Form Design, Second Edition, Part Four, Dosage Form Design and Manufacture, Chapter 33, “Transdermal Drug Delivery” 2007: 499 –533.
13. Merkle, H.P., Transdermal delivery system: Methods find, Expclinpharmacol‚1989: 11; 135-35.